Angela Lamarca, Liver Cancer Summit 2022: The Latest Advances in Hepatic-biliary Oncology
touchONCOLOGY caught up with Professor Angela Lamarca (Christie NHS Foundation Trust, Manchester, UK) to discuss her highlights from the Liver Cancer Summit 2022, targeted therapies for cholangiocarcinoma and some of the most important current trial data in hepatic-biliary oncology (the HIMALAYA and TOPAZ-1 studies).
- What were your highlights and hot topics from the Liver Cancer Summit 2022? 00:20-00:58
- How are targeted therapies changing the treatment paradigm for cholangiocarcinoma? 00:58-02:07
- Could you tell us a little about the HIMALAYA study? 02:07-02:48
- How will the results from the phase III TOPAZ-1 trial impact clinical practice for patients with advanced cholangiocarcinoma? 02:48-03:17
- What do you consider the main unmet educational needs in hepatic-biliary oncology? 03:17-04:04
Speaker Disclosure: Angela Lamarca has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the Liver Cancer Summit 2022
Share this Video
Related Videos In Gastrointestinal Cancers
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!